In the phase 3 NEAT trial, eDSP was well tolerated but did not significantly reduce neurological symptoms in patients with ataxia-telangiectasia. Topline data were announced from a phase 3 trial ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results